LILRB1 and myelodysplastic syndrome: Relevant to the above considerations on immune checkpoints, cDC1s from MDS patients showed huge upregulation of ILT2 and downregulation of TIM-3 expression, thus denoting an overall subversion of their inhibitory molecule repertoire.